Table 3. Attainment of lipid targets at follow-up based on therapy at discharge.
| Therapy | AHA/ACC 2018 Guideline | ESC/EAS 2019 Guideline | ESC/EAS 2016 Guideline | ||
|---|---|---|---|---|---|
| LDL ≥1.8 mmol/L (70 mg/dL) threshold | LDL-C <1.4 mmol/L (54 mg/dL) | Non-HDL-C <2.2 mmol/L (85 mg/dL) | LDL-C <1.8 mmol/L (70 mg/dL) | Non-HDL-C <2.6 mmol/L (100 mg/dL) | |
| Overall (n=484) | 253 (52.3) | 118 (24.4) | 140 (28.9) | 231 (47.7) | 237 (49.0) |
| High-intensity statin plus ezetimibe (n=46) | 15 (32.6) | 14 (30.4) | 17 (37.0) | 31 (67.4) | 27 (58.7) |
| High-intensity statin only (n=379) | 197 (52.0) | 98 (25.9) | 115 (30.3) | 182 (48.0) | 193 (50.9) |
| Moderate- or low-intensity statin with or without ezetimibe (n=44) | (70.5) | 4 (9.1) | 5 (11.4) | 13 (29.5) | 12 (27.3) |
| Ezetimibe only (n=3) | 3 (100) | 0 | 0 | 0 | 0 |
Data are presented as count (percent).
AHA/ACC, American Heart Association/American College of Cardiology; ESC/EAS, European Society of Cardiology/European Atherosclerosis Society; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.